|
|
|
|
|
|
By Elben Guimaraes, upstream manufacturing expert | Each approach has its advantages and drawbacks, making the decision-making process crucial for your organization. This comprehensive guide is designed to help you determine which option, or possibly a hybrid strategy, is the most suitable for your company’s unique needs and goals. |
|
|
|
|
|
| Methods For mRNA Poly(A) Sizing | Poster | By Lauren Hinkel, Ryan Williams, Calleigh Herren, and Theresa Legan, Vernal Biosciences | This study used Oxford Nanopore Technologies' Direct RNA Sequencing Kit and obtained successful sizing of poly(A) tail regions. The results are presented in a histogram and table format. |
|
|
| Integrated Solutions For Advanced Therapies | White Paper | Catalent | The right CDMO offering integrated services can ease increasingly common CGT manufacturing problems such as scale, raw material access, viral vector production, and quality requirements. |
|
|
| Next-Generation CRISPR Approaches | White Paper | Aldevron | By providing essential components like nucleases, gRNAs, and HDR templates, a reliable CDMO facilitates a seamless transition from discovery research to clinical trials and beyond. |
|
|
|
|
|
|
| It's no secret that on-going research aims to improve the efficacy and specificity of non-viral approaches for genetic engineering. But the field is rapidly evolving with research aimed at improving transfection efficiency, targeting, and safety profiles of non-viral delivery systems. Join Cell & Gene Live to discuss the most notable approaches and recent breakthroughs as well as promising non-viral vectors used in clinical trials. Attendance is free thanks to the support of MaxCyte. |
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
 468x60.png)
